This episode covers the Trump administration's rollout of reciprocal tariffs on 60 trading partners, followed by a 90-day pause after market turmoil, with health systems anticipating significant supply cost increases despite pharmaceuticals being initially exempted. The episode also discusses insights from a health strategy leadership forum, CMS's 5.1% Medicare Advantage rate increase for 2026, and UnitedHealth Group shareholders dropping a proposal for annual reporting on prior authorization practices.
